ESPERITE overview

Transaction highlights · Esperite NV secures an external financing of up to EUR 35 million through further private placements of convertible notes with share subscription warrants attached over a period of 36 months, subject to fulfillment of certain conditions · The Warrants, if exercised, are leading to an additional EUR 35 million proceeds over a period of 5 years · Bridge note of EUR 150,000 issued today · Subscription by European Small Caps Opportunities Fund, based in Australia ·...

Esperite confirms that the Swiss prosecutor launched a preliminary penal investigation into the activities of its former subsidiary CryoSave after several clients and third parties have alerted the Swiss Public Health Authorities over the transport of their samples. The former Director of CryoSave, Frederic Amar who was in office from January 2016 to September 2019 is therefore also under this investigation. Esperite declares that this indictment will allow its Director, Frederic Amar to defend...

Esperite N.V. (Euronext: ESP, “Esperite”) announces that it has convened an Extraordinary General Meeting of Shareholders (“EGM”) to be held on 26 March 2020 at 14:00 hours CET at Immeuble le Patio, 35-37 Rue Louis Guérin, 69100 Villeurbanne, France The EGM's convocation notice, agenda and the explanatory notes to the agenda and further EGM materials can be downloaded from Esperite's website. ( www.esperite.com ) Shareholders interested in attending the EGM are invited to contact...

Samples and Database are safe Amsterdam, The Netherlands – 10 February 2020 Esperite N.V. (Euronext: ESP, “Esperite”) has noticed several articles in the news, online channels and information blogs about a hypothetical loss of umbilical cord blood samples during the transport from Belgium, Switzerland to Poland. Esperite has published since September 26th 2019 a CryoSave section on its website which describes the different steps from the transaction with the Polish partner, Myrisoph and...

ESPERITE (ESP) is not bankrupt. Amsterdam, The Netherlands – 30 October 2019 The court in Zutphen has annuled the bankruptcy of the company. Esperite and its management have worked on a restructuring plan and will present very soon its new strategy during a Extraordinary General Meeting with its shareholders. To learn more about the ESPERITE Group, [email protected] or visit the website at www.esperite.com , *** This press release contains inside information as referred to in article 7...

Amsterdam, The Netherlands – 14 October 2019 The Court in Gelderland, Netherlands, on October 8 th , 2019, has declared Esperite in bankruptcy. The board of directors of Esperite N.V. disputes the verdict and will appeal the order. Esperite N.V. will keep all interested parties informed. Esperite N.V. (Euronext: ESP, “Esperite” or “the Group”) announces To learn more about the ESPERITE Group, [email protected] or visit the website at www.esperite.com , Attachment PR - 14 October...

Esperite N.V. (ESP) : Update to the market on its Cord Blood Stem Cells Subsidiaries and activity. Amsterdam, The Netherlands – 1st October 2019 Esperite N.V. (the Group) confirmed on 22nd February 2019 the intentions of the Group to sell its Cord Blood Stem Cells activities in an transaction composed by two main elements. The Storage Agreement signed between CryoSave AG and its new Polish partner, which main advantages is to consolidate all the samples from different country in one secured...

CryoSave has maintained without compromise the high-quality processing and storage services and has handed over its whole business. Switzerland – 19 September 2019 CryoSave has since its establishment in 2000, ensured the best security for its clients and has a proven track record of professionalism and expertise in the field of stem cells banking, recognized by the medical community. CryoSave is one of the largest and longest operating stem cell banks in Europe, having stored more than...